|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Trading investments at fair value (cost of $37,326 and $37,606, respectively) | ||||||||||||||||||||
| Available-for-sale investments at fair value (cost of $2,956,353 and $1,812,408, respectively) | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Loans held for investment (net of allowance for losses of $1,449,614 and $1,430,318, respectively) | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other interest-earning assets | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Goodwill and acquired intangible assets, net | ||||||||||||||||||||
| Income taxes receivable, net | ||||||||||||||||||||
| Tax indemnification receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term borrowings | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Series B: 2.5 million and 2.5 million shares issued, respectively, at stated value of $100 per share | ||||||||||||||||||||
| Total series B: 2.5 million and 2.5 million shares issued, respectively, at stated value of $100 per share | ||||||||||||||||||||
| Common stock, par value $0.20 per share, 1.125 billion shares authorized: 445.7 million and 443.2 million shares issued, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss (net of tax benefit of ($27,386) and ($13,446), respectively) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total SLM Corporation stockholders’ equity before treasury stock | ||||||||||||||||||||
| Less: Common stock held in treasury at cost: 262.9 million and 244.0 million shares, respectively | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
